In sum, in relation to the hypothesis that involves the entry mechanism of SARS-CoV-2 in the lung and the RAS imbalance in favor of the proinflammatory effects of Ang II stimulating AT1 receptors, we consider that the results of the clinical trials described using ARBs will have to be interpreted depending on severity and stage of disease and in light of the start time of their prescription related to the time of diagnosis of COVID-19 as well as the administered daily dose and duration of treatment. The gene discussed is AGTR1; the disease is COVID-19.